Stockscreener 앱 받기
7.55
0.80%
0.06
전일 마감가:
$7.49
열려 있는:
$7.59
하루 거래량:
463.81K
Relative Volume:
3.84
시가총액:
$257.86M
수익:
$21.25M
순이익/손실:
$-16.05M
주가수익비율:
-12.38
EPS:
-0.61
순현금흐름:
$-17.14M
1주 성능:
+0.00%
1개월 성능:
-2.96%
6개월 성능:
-9.25%
1년 성능:
+23.57%
1일 변동 폭
$7.45
$7.63
1주일 범위
$7.35
$7.74
52주 변동 폭
$4.68
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
명칭
Fennec Pharmaceuticals Inc
전화
(919) 636-4530
주소
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
FENC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
7.55 | 255.81M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | 개시 | CapitalOne | Overweight |
| 2022-08-08 | 재개 | Craig Hallum | Buy |
| 2020-06-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-11 | 개시 | Goldman | Buy |
Fennec Pharmaceuticals Inc 주식(FENC)의 최신 뉴스
Fennec's Pedmarqsi gets nod from U.K. regulators - MSN
Fennec Pharmaceuticals Announces Private Offering to Bolster Financial Position - MSN
(FRX) Risk-Controlled Trading Report (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Pfizer (PFE) - The Globe and Mail
How To Trade (FRX) (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Tumors - marketscreener.com
Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment - TipRanks
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors - marketscreener.com
Fennec Pharma announces City of Hope PEDMARK trial in metastatic testicular tumors | FENC Stock News - Stock Titan
(FRX) Trading Performance and Risk Management (FRX:CA) - news.stocktradersdaily.com
Retail Surge: Will Fennec Pharmaceuticals Inc RV41 stock hit Wall Street targetsMarket Volume Report & Real-Time Sentiment Analysis - BỘ NỘI VỤ
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus
Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares for $75,400 - Investing.com
Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares for $75,400 By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Director Sells 10,000 Shares - TradingView
Dir Raykov Sells 10,000 ($75.4K) Of Fennec Pharmaceuticals Inc [FENC] - TradingView
Dir Raykov Files To Sell 10,000 Of Fennec Pharmaceuticals Inc [FENC] - TradingView
What hedge fund moves indicate for Fennec Pharmaceuticals Inc. (RV41) stockQuarterly Portfolio Report & Safe Investment Capital Preservation Plans - Newser
Will Fennec Pharmaceuticals Inc. (RV41) stock hit Wall Street targetsTake Profit & Fast Entry High Yield Tips - Newser
Can Fennec Pharmaceuticals Inc. (RV41) stock withstand sector downturns2025 Trade Ideas & Expert Verified Stock Movement Alerts - Newser
How analysts revise price targets for Fennec Pharmaceuticals Inc. (RV41) stockJuly 2025 Breakouts & Safe Entry Point Identification - Newser
(FENC) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Will Fennec Pharmaceuticals Inc. (RV41) stock benefit from Fed rate cutsDay Trade & Smart Allocation Stock Reports - Newser
Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan - MSN
Why Fennec Pharmaceuticals Inc. stock is popular among millennialsMarket Weekly Review & Daily Volume Surge Signals - Newser
(FRX) Technical Pivots with Risk Controls (FRX:CA) - news.stocktradersdaily.com
Is Fennec Pharmaceuticals Inc. stock resilient to inflationInflation Watch & Fast Entry Momentum Alerts - Newser
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Can Fennec Pharmaceuticals Inc. stock attract ESG capital inflows2025 Bull vs Bear & Technical Pattern Based Buy Signals - Newser
Fennec Pharmaceuticals : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Stocks in play: Fennec Pharmaceuticals Inc. - The Globe and Mail
Fennec Pharmaceuticals Inc Announces Positive Results from PEDMARK® Trial in Japan - TradingView
Wedbush on Fennec Pharmaceuticals Latest Japan Trial Results - marketscreener.com
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power - Benzinga
Fennec Pharmaceuticals announces positive topline results - marketscreener.com
Fennec Pharmaceuticals Inc. Announces Positive Topline Results from Investigator-Initiated Clinical Study of Pedmark®? in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Reports Positive Top-line Results From Japan Trial - marketscreener.com
Fennec Pharmaceuticals Says its Phase 2/3 Trial of Pedmark in Japan Meets Primary Endpoint - marketscreener.com
Fennec’s pediatric hearing protection drug shows positive results in Japan By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Brief: Announcing "Positive" Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss - The Manila Times
Is Fennec Pharmaceuticals Inc. (RV41) stock a buy before new product rolloutQuarterly Trade Report & Daily Stock Trend Reports - Newser
(FRX) Long Term Investment Analysis (FRX:CA) - news.stocktradersdaily.com
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33 - Defense World
(FRX) Technical Data (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
Loss-Making Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Expected To Breakeven In The Medium-Term - Yahoo Finance
Trend Tracker for (FRX) (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals highlights cisplatin ototoxicity risks - Traders Union
(FENC) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Fennec Pharmaceuticals Inc (FENC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):